AZD1222 delivers strong immune response in phase I/II Covid-19 vaccine trial

This article was originally published here

AZD1222 was co-invented by Oxford University and its spin-out company Vaccitech. The recombinant adenovirus vaccine, which was licensed by AstraZeneca in May 2020, was tolerated by the participants

The post AZD1222 delivers strong immune response in phase I/II Covid-19 vaccine trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply